ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rituximab and tocilizumab"

  • Abstract Number: 2823 • 2018 ACR/ARHP Annual Meeting

    Comparative Long-Term Effectiveness of Switching to Another Tumour Necrosis Factor Antagonists, Tocilizumab or Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to a First-Line TNF Inhibitor

    Daniela Santos Faria1, Mónica Eusébio2, Joana Leite Silva3, Joana Ramos Rodrigues1, Joana Sousa Neves1, Ana Catarina Duarte4, Carina Lopes5, Ana Valido6, Joana Dinis6, João Freitas7, Mariana Santiago7, Raquel Ferreira8, Sara Ganhão9, Luís Cunha Miranda10, Daniela Peixoto1, Filipa Teixeira1, Sérgio Alcino1, Carmo Afonso1, José Tavares Costa3 and Maria José Santos11, 1Rheumatology, ULSAM, Ponte de Lima, Portugal, 2Sociedade Portuguesa de Reumatologia, Lisboa, Portugal, LIsboa, Portugal, 3Rheumatology, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, 4Rheumatology, Hospital Garcia de Orta, Almada, Portugal, 5Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, 6Rheumatology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, 7Rheumatology, Centro Hospitalar e Universitário de Coimbra, CHUC-EPE, Coimbra, Portugal, 8Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, 9Rheumatology, Centro Hospitalar de São João, Porto, Portugal, 10Instituto Português de Reumatologia, Lisbon, Portugal, 11Reuma.pt, Almada, Portugal, Almada, Portugal

    Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are highly effective treatments for active Rheumatoid Arthritis (RA). However, up to 40% of patients either fail to respond…
  • Abstract Number: 1998 • 2016 ACR/ARHP Annual Meeting

    Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis Indicate a Similar Safety but a Different Drug Retention Between Abatacept, Rituximab and Tocilizumab

    Jacques-Eric Gottenberg1, Jacques Morel2, Arnaud Constantin3, Thomas Bardin4, Alain G. Cantagrel5, Bernard Combe6, Maxime Dougados7, Rene-Marc Flipo8, Alain Saraux9, Thierry Schaeverbeke10, Jean Sibilia11, Martin Soubrier12, Olivier Vittecoq13,14, Elodie Perrodeau15, Philippe Ravaud16, Xavier Mariette17 and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, 1Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 2Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, 3Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, 4Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, 5Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, 6Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 7Rheumatology, Paris Descartes University, Paris, France, 8Rheumatology, University Hospital, Lille, France, 9Rheumatology, Brest University Hospital, Brest, France, 10Rheumatology, CHU Bordeaux, Bordeaux, France, 11Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 12Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 13Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, 14Rheumatology, Rouen University Hospital, Rouen, France, 15Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 16Epidemiologist, PARIS, France, 17Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France

    Three non-TNF targeted biologics – rituximab, abatacept, and tocilizumab – are widely used, notably in TNF-IR patients. We aimed to compare the efficacy and safety…
  • Abstract Number: 2613 • 2016 ACR/ARHP Annual Meeting

    Seropositivity for RF or ACPA Predicts Long Term Drug Retention with Rituximab, but Not with Abatacept and Tocilizumab : Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis

    Jacques-Eric Gottenberg1, Jacques Morel2, Arnaud Constantin3, Thomas Bardin4, Alain G. Cantagrel5, Bernard Combe6, Maxime Dougados7, Rene-Marc Flipo8, Alain Saraux9, Thierry Schaeverbeke10, Jean Sibilia11, Martin Soubrier12, Olivier Vittecoq13, Elodie Perrodeau14, Philippe Ravaud15, Xavier Mariette16 and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, 1Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 2Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, 3Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, 4Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, 5Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, 6Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 7Rheumatology, Paris Descartes University, Paris, France, 8Rheumatology, University Hospital, Lille, France, 9Rheumatology, Brest University Hospital, Brest, France, 10Rheumatology, CHU Bordeaux, Bordeaux, France, 11Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 12Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 13Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, 14Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 15Epidemiologist, PARIS, France, 16Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France

    Background/Purpose: Seropositivity for RF or ACPA is associated with a better short-term effectiveness and drug retention of abatacept (ABA) and rituximab (RTX). Data are very…
  • Abstract Number: 1614 • 2016 ACR/ARHP Annual Meeting

    Monotherapy with Abatacept, Rituximab or Tocilizumab Is Not Associated with a Significantly Lower Long Term Retention Than Combination with Synthetic DMARD: Long-Term Registry Data in 4498 Real-Life Patients with Rheumatoid Arthritis

    Jacques-Eric Gottenberg1, Jacques Morel2, Arnaud Constantin3, Thomas Bardin4, Alain G. Cantagrel5, Bernard Combe6, Maxime Dougados7, Rene-Marc Flipo8, Alain Saraux9, Thierry Schaeverbeke10, Jean Sibilia11, Martin Soubrier12, Olivier Vittecoq13, Elodie Perrodeau14, Philippe Ravaud15, Xavier Mariette16 and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, 1Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 2Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, 3Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, 4Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, 5Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, 6Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 7Rheumatology, Paris Descartes University, Paris, France, 8Rheumatology, University Hospital, Lille, France, 9Rheumatology, Brest University Hospital, Brest, France, 10Rheumatology, CHU Bordeaux, Bordeaux, France, 11Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 12Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 13Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, 14Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 15Epidemiologist, PARIS, France, 16Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France

    Background/Purpose: Data are very limited concerning the association between cotreatment with a conventional synthetic DMARD (csDMARD) and long term retention of abatacept (ABA), rituximab (RTX) and tocilizumab…
  • Abstract Number: 1524 • 2014 ACR/ARHP Annual Meeting

    Rituximab Done! What’s Next in RA?

    Ulrich A. Walker1, Veronika K. Jaeger1, Katerina Chatzidionysiou2, Merete Lund Hetland3,4, Ellen Margrethe Hauge3,4, Karel Pavelka5, Dan C. Nordström6, Helena Canhao7, Matija Tomsic8, Ronald van Vollenhoven2 and Cem Gabay9, 1Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, 2Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, 3Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, 4DANBIO, Center for Rheumatology and Spine Diseases, Glostrup University Hospital, Glostrup, Denmark, Glostrup, Denmark, 5Charles University, Prague, Czech Republic, Prague, Czech Republic, 6ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, Helsinki, Finland, 7Rheumatology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal on behalf of the Rheumatic Diseases Portugal Register, Lisbon, Portugal, 8Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia, 9University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland

    Background/Purpose The optimal strategy to use biologics after rituximab (RTX) in RA is unknown. We therefore aimed to evaluate the effectiveness of different biologics after…
  • Abstract Number: 1152 • 2014 ACR/ARHP Annual Meeting

    Euroqol-5-Dimensions Utility Gain in Rheumatoid Arthritis, Treated with Abatacept, Rituximab, Tocilizumab or Tumor Necrosis Factor Inhibitors

    Anders Gülfe1, Johan A. Karlsson2 and Lars-Erik Kristensen3, 1Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, 2Dept of Clinical Sciences, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, 3Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Malmö, Sweden

    Background/Purpose: We have earlier demonstrated that EuroQoL-5-Dimensions (EQ-5D) utility improves rapidly after commencement of tumor necrosis factor inhibition (TNFi) in rheumatoid arthritis (RA) and other…
  • Abstract Number: 511 • 2014 ACR/ARHP Annual Meeting

    First and Second Line Continuation Rates of Non Anti-TNF-α Biological DMARD for the Treatment of Rheumatoid Arthritis

    Tristan Pascart1, Rene-Marc Flipo2, Xavier Deprez3 and Eric Houvenagel4, 1Rheumatology, Saint-Philibert Hospital, Lille, France, 2Rheumatology, University Hospital Lille, Lille, France, 3Rhumatologie, Ch De Valenciennes, Valenciennes, France, 4Rheumatology, Saint-Philibert Hospital, LOMME, France

    Background/Purpose The 2013 update of the EULAR recommendations for the management of RA with synthetic and biological DMARDs set non-anti-TNF- α as first-line biological treatments.…
  • Abstract Number: 497 • 2014 ACR/ARHP Annual Meeting

    Efficacy and Safety Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed By Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to Traditional Disease Modifying Anti-Rheumatic Drugs

    Thomas Dörner1, Hans-Peter Tony2, Gerd Burmester1, Hendrik Schulze-Koops3, Jörg Kaufmann4, Peter Kästner5, Herbert Kellner6, Reiner Kurthen7, Sylke Wagner8, Marvin A. Peters9 and Christoph Iking-Konert10, 1Charité - Universitätsmedizin Berlin, Berlin, Germany, 2University Clinic Wuerzburg, Wuerzburg, Germany, 3University Clinic Munich, Munich, Germany, 4Rheumatology Practice, Ludwigsfelde, Germany, 5MVZ Out-patient Rheumatogy Unit Erfurt, Erfurt, Germany, 6Specialist Practice for Rheumatology and Gastroenterology, Munich, Germany, 7Rheumatology Practice, Aachen, Germany, 8Practice for Internal Medicine specialized in Rheumatology, Halle, Germany, 9Roche Pharma AG, Grenzach-Wyhlen, Germany, 10University Clinic Hamburg-Eppendorf, Hamburg, Germany

    Background/Purpose: The MIRAI study evaluated a sequential exposure to 2 defined biologics under rigorous study conditions within a homogeneous population of biological naïve patients (pts)…
  • Abstract Number: 2690 • 2013 ACR/ARHP Annual Meeting

    Survival Of The Second Biologic After The First Tumor Necrosis Factor Alpha Inhibitor’s Failure In The Treatment Of Rheumatoid Arthritis: Prospective Observational Data From Biorx.Si Registry

    ŽIga Rotar1 and Matija Tomsic2, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia

    Background/Purpose: Current recommendations for management of RA propose a tumor necrosis factor alpha inhibitor (TNFi) for patients failing to achieve the treatment target with synthetic…
  • Abstract Number: 436 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Study Of a Sequential Therapy Of Tocilizumab and, If Initially Inadequately Responded To Tocilizumab, Followed By Rituximab In Patients With Rheumatoid Arthritis and Inadequate Response To Traditional Disease Modifying Anti-Rheumatic Drugs (MIRAI)-Interim Analysis 2

    Thomas Doerner1, Hans Peter Tony2, Hendrik Schulze-Koops3, Jörg Kaufmann4, Peter Kaestner5, Herbert Kellner6, Reiner Kurthen7, S. Wagner8, Marvin A. Peters9 and Christof Iking-Konert10, 1Dept Int Med (Charite), Humdoldt Univ, Berlin, Germany, 2Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, 3Division of Rheumatology, University of Munich, Munich, Germany, 4Ambulant Centres for Rheumatology, Rheumatologist, Ludwigsfelde, Germany, 5Outpatient Department of Rheumatology, Ambulantes Rheumazentrum Erfurt, Germany,, Erfurt, Germany, 6Centre for Inflammatory Joint Diseases, Munich, Germany, 7Rheumapraxis, Aachen, Germany, 8Internistische Schwerpunktpraxis für Rheumatologie, Halle, Germany, 9Roche Pharma AG, Grenzach-Wyhlen, Germany, 10Department of Rheumatology, University Hospital Hamburg Eppendorf, Hamburg, Germany

    Background/Purpose: The MIRAI study evaluates a sequential exposure to two defined biologics under rigorous study conditions within a homogeneous population of patients (pts) who inadequately…
  • Abstract Number: 1326 • 2012 ACR/ARHP Annual Meeting

    Efficacy of Different Biologic Agents for Improving Physical Function As Measured by the Health Assessment Questionnaire: A Meta-Analysis with Indirect Comparisons

    Lillian J. Barra1, Andrew Ha2, Louise Sun3, Catarina Fonseca4 and Janet E. Pope5, 1Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, 2The University of Toronto, Toronto, ON, Canada, 3University of Ottawa, Ottawa, ON, Canada, 4Universidade de Lisboa, Lisbon, Portugal, 5Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada

    Background/Purpose:   The Health Assessment Questionnaire (HAQ) is a patient-centred, validated measure of physical function. It is predictive for disability, morbidity and mortality. The efficacy…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology